RAS Mutations Enhance Chemotherapy in AML

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD

July 14th 2025

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Best Practices for the Medical Oncology Boards

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Ariana Pelosci

Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.

July 14th 2025

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.

Related Content

Caroline Oska;Eleni Kohilakis;Jana Fox

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD

July 14th 2025

Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Best Practices for the Medical Oncology Boards

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Ariana Pelosci

Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype

Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.